136 related articles for article (PubMed ID: 18676243)
1. [1,2,6-tri-O-galloyl-beta-D-glucopyranose inhibits gp41-mediated HIV envelope fusion with target cell membrane].
Sun W; Wang HT; Xia CL; Wu SG; Jiang SB; Jiang ZH; Liu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1127-31. PubMed ID: 18676243
[TBL] [Abstract][Full Text] [Related]
2. Tannin inhibits HIV-1 entry by targeting gp41.
Lü L; Liu SW; Jiang SB; Wu SG
Acta Pharmacol Sin; 2004 Feb; 25(2):213-8. PubMed ID: 14769212
[TBL] [Abstract][Full Text] [Related]
3. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
5. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
6. Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41.
Gallo SA; Clore GM; Louis JM; Bewley CA; Blumenthal R
Biochemistry; 2004 Jun; 43(25):8230-3. PubMed ID: 15209519
[TBL] [Abstract][Full Text] [Related]
7. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
Melikyan GB; Egelhofer M; von Laer D
J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
[TBL] [Abstract][Full Text] [Related]
8. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
Korazim O; Sackett K; Shai Y
J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
[TBL] [Abstract][Full Text] [Related]
9. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.
Vaillant A; Juteau JM; Lu H; Liu S; Lackman-Smith C; Ptak R; Jiang S
Antimicrob Agents Chemother; 2006 Apr; 50(4):1393-401. PubMed ID: 16569857
[TBL] [Abstract][Full Text] [Related]
10. [Isolation and characterization of the anti-HIV active component from Eucommia ulmoides].
Lv L; Sun YR; Xu W; Liu SW; Rao JJ; Wu SG
Zhong Yao Cai; 2008 Jun; 31(6):847-50. PubMed ID: 18998566
[TBL] [Abstract][Full Text] [Related]
11. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
Liu S; Boyer-Chatenet L; Lu H; Jiang S
J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
[TBL] [Abstract][Full Text] [Related]
12. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.
Jin BS; Lee WK; Ahn K; Lee MK; Yu YG
J Biomol Screen; 2005 Feb; 10(1):13-9. PubMed ID: 15695339
[TBL] [Abstract][Full Text] [Related]
14. A mammalian two-hybrid system-based assay for small-molecular HIV fusion inhibitors targeting gp41.
Shui X; Lu X; Gao Y; Liu C; Ren F; Jiang Q; Zhang H; Zhao B; Zheng Z
Antiviral Res; 2011 Apr; 90(1):54-63. PubMed ID: 21352856
[TBL] [Abstract][Full Text] [Related]
15. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Zou P; Avan I; Ibrahim TS; Abo-Dya NE; Abdelmajeid A; Debnath AK; Katritzky AR
Bioorg Med Chem Lett; 2011 Nov; 21(22):6895-8. PubMed ID: 21978673
[TBL] [Abstract][Full Text] [Related]
17. A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection.
Yang J; Li L; Tan S; Jin H; Qiu J; Mao Q; Li R; Xia C; Jiang ZH; Jiang S; Liu S
Fitoterapia; 2012 Mar; 83(2):348-55. PubMed ID: 22155187
[TBL] [Abstract][Full Text] [Related]
18. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.
Yu H; Tudor D; Alfsen A; Labrosse B; Clavel F; Bomsel M
Retrovirology; 2008 Oct; 5():93. PubMed ID: 18925934
[TBL] [Abstract][Full Text] [Related]
19. Hexapeptides that interfere with HIV-1 fusion peptide activity in liposomes block GP41-mediated membrane fusion.
Gómara MJ; Lorizate M; Huarte N; Mingarro I; Perez-Payá E; Nieva JL
FEBS Lett; 2006 May; 580(11):2561-6. PubMed ID: 16647705
[TBL] [Abstract][Full Text] [Related]
20. [A non-infectious and quantitative cell-based bioassay for screening HIV entry inhibitors targeting HIV envelope proteins].
Li MM; Xia CL; Mao QC; Jiang SB; Liu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):941-4. PubMed ID: 20501362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
